Background and objective: The 6-min walk test (6MWT) is the most widely utilized method of assessing exercise capacity in pulmonary arterial hypertension (PAH). Cardiopulmonary exercise testing has the advantage of providing additional physiological information over 6MWT. The goals of our study were to describe the addition of gas exchange measurements to 6MWT and to determine how these parameters were related to the severity of PAH in three major subgroups of PAH (idiopathic (IPAH), connective tissue diseaserelated (CTPAH) and congenital heart disease-related (CHPAH)). Methods: Seventy-six PAH patients (IPAH, n = 28; CTPAH, n = 24; CHPAH, n = 24) completed the 6MWT with simultaneous gas exchange measurements. The 6-min walk distance (6MWD), oxygen uptake ( _ VO 2 ), carbon dioxide production ( _ VCO 2 ), oxygen saturation, minute ventilation to carbon dioxide output ( _ V E / _ VCO 2 ) and end-tidal partial pressure for carbon dioxide (P ET CO 2 ) were compared between subgroups, different functional classes (FCs) and pharmacotherapy. Results: Whilst no significant difference in 6MWT was observed, absolute _ VO 2 and _ VCO 2 were higher for IPAH (P < 0.05). Differences were removed when _ VO 2 and _ VCO 2 were expressed relative to body mass (i.e. mL/kg/ min). CHPAH had the most significant desaturation during 6MWT (CPAH: 73 AE 15%; CTPAH: 90 AE 8%, IPAH: 92 AE 8%, P < 0.01). There was no difference in _ V E / _ VCO 2 and P ET CO 2 between groups; however, New York Health Association (NYHA) FC II performed better than FC III subjects in 6MWT with lower _ V E / _ VCO 2 and higher end-exercise P ET CO 2 . Similarly, individuals on more advanced pharmacotherapy (triple therapy vs monotherapy) had poorer gas exchange during exercise. Conclusion: Whilst 6MWT and gas exchange did not differentiate between PAH groups, individuals with more
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a rare but serious disease characterized by elevated mean pulmonary arterial pressure and pulmonary vascular resistance (PVR). 1 Despite the diversity of aetiologies, patients with PAH typically present with exercise intolerance, progressive worsening in dyspnoea and, if left untreated, right ventricular failure and premature death. 2 While modern PAH-specific therapies can improve symptoms and possibly decrease the rate of clinical deterioration in some PAH patients, most
SUMMARY AT A GLANCE
Pulmonary arterial hypertension (PAH) patients have reduced exercise tolerance and characteristic gas exchange responses. Inclusion of gas exchange measurements during the 6-min walk test showed that individuals with more severe disease and more advance pharmacotherapy had poorer gas exchange during exercise.
remain symptomatic with reduced exercise capacity, quality of life and survival despite optimized medical treatment. 2 Current guidelines recommend evaluation of exercise capacity in the assessment and follow-up of PAH, 3 with the 6-min walk test (6MWT) being the most widely utilized method of evaluation. 3 In countries such as Australia, 6MWT has been requirement for ongoing pharmaceutical benefits scheme allowance and is typically conducted at each clinic visit. This is because 6MWT is non-invasive, well-defined with standardized guidelines, simple to undertake 3 and the primary outcome, the 6-min walk distance (6MWD), has been shown to predict morbidity and mortality in PAH. 4, 5 While 6MWD has been accepted by regulatory authorities as an end-point for evaluating treatment effects in PAH, the test is not without its limitations. 6, 7 Specifically, 6MWT lacks sensitivity and specificity in the diagnosis of PAH, has a significant plateau effect, is not used in an age-adjusted fashion and provides no physiological details in the determinants of exercise limitation. 5, 7, 8 There is also evidence that a change in 6MWD is a poor surrogate end-point for clinical events. 9 As a result, recent studies evaluating treatment effects in PAH have moved away from using 6MWD as a primary end-point. 7 Current guidelines also recommend cardiopulmonary exercise testing (CPET) in evaluating exercise capacity in PAH, with peak oxygen consumption ( _ VO 2peak ) being a recognized prognostic indicator for the disease. 7, 10 Unlike the 6MWT, CPET provides additional information on physiological limitations in PAH, particularly when other differential diagnoses are being considered. 11 Ventilatory inefficiency in PAH is a distinctive physiological abnormality characterized by an increase in minute ventilation to carbon dioxide output ( _ V E / _ VCO 2 ) and a lower end-tidal partial pressure for carbon dioxide (P ET CO 2 ), 12 which are observed both prior to and during exercise. Alteration in _ V E / _ VCO 2 and P ET CO 2 during CPET has been shown to correlate with PAH disease severity and prognosis. 11, 13, 14 However, CPET is used far less commonly than 6MWT in the clinical setting, partly because in order to conduct a CPET, an ergometer, a metabolic cart to measure gas exchange, and expertise in the administration and interpretation of the test are required. 15 Moreover, medical supervision is mandatory in this high-risk population as recommended by the guidelines. 15 Recent studies have found that the addition of gas exchange measurements to an exercise test such as 6MWT may be feasible and that the exercise oxygen uptake ( _ VO 2 ) at completion of 6MWT correlated with that achieved during an incremental CPET. 16, 17 Woods et al. 18 reported that during a 3-min submaximal exercise test, both _ V E / _ VCO 2 and P ET CO 2 differentiated PAH patients from healthy controls and discriminated between different severities of PAH.
The goals of our study were to describe the addition of gas exchange measurements to 6MWT and to determine how these parameters were related to the severity of PAH. We hypothesized that patients with more severe PAH have worse gas exchange parameters (i.e. higher end-exercise _ V E / _ VCO 2 and lower P ET CO 2 ).
METHODS

Patient population
Seventy-six consecutive adult Group I PAH patients attending a tertiary pulmonary hypertension referral centre were included in this study. Subjects were further categorized into three subtypes according to their diagnosis: idiopathic PAH (IPAH, n = 28), connective tissue disease-related PAH (CTPAH, n = 24) and congenital heart disease-related PAH (CHPAH, n = 24). In addition, each subject was given a functional classification (New York Health Association (NYHA) Functional Class (FC) I, II, III or IV) at the time of the 6MWT by their attending physician. The study was approved by The Human Research Ethics Committee (HREC/14/ QPCH/47) and all subjects gave written informed consent prior to commencement.
The 6-min walk test
The 6MWT was conducted using a standardized protocol. 19 Each subject completed the 6MWT whilst wearing a portable metabolic system (Metamax, Cortex BXB, Lepzig, Germany). At each minute of the 6MWT, severity of dyspnoea was determined using a 0-10 scale of breathlessness.
Ventilatory expired gas analysis
During the 6MWT, each subject breathed through a mask (Hans Rudolph, Kansas City, MO, USA) for the collection and analysis of expired gases. The metabolic system was calibrated for volume and expired concentrations of oxygen and carbon dioxide prior to each test. Minute-by-minute measurements of _ VO 2 , carbon dioxide production ( _ VCO 2 ), minute ventilation ( _ V E ), _ V E / _ VCO 2 , P ET CO 2 and oxygen saturation (S p O 2 ) were recorded. Oxygen pulse ( _ VO 2 /HR (heart rate)) was also calculated.
Echocardiographic evaluation
As part of standard clinical protocol, all subjects completed echocardiographic evaluation of cardiac function on the same day as their 6MWT. Echocardiographic images were acquired using a 4-MHz matrix array cardiac transducer (Vivid 7, General Electric, Milwaukee, WI, USA) with each subject in a semi-recumbent position. Right ventricular systolic pressure (RVSP) was determined from the tricuspid regurgitation (TR) velocity as per standard guidelines. 20 RV systolic function was examined by assessing the tricuspid annular plane systolic excursion (TAPSE).
Statistical analysis
All statistical comparisons were performed using the SPSS statistical software package (Version 12.0, SPSS Inc., Chicago, IL, USA). The 6MWT and gas exchange responses were compared between PAH subgroups based on aetiology, NYHA FC and pharmacotherapy using parametric/non-parametric one-way analysis or ttests as required. With multiple comparisons, where significant differences were found, contrasts (Bonferroni and Dunnett's tests for parametric and non-parametric data, respectively) were used to determine the source of group differences. Where required, a chi-square test was used to compare differences in categorical groups. A Fisher's exact test was used where the expected numbers were small and the criteria for using chi-square test could not be met.
RESULTS
Baseline characteristics of the subjects are shown in Table 1 . Subjects in the IPAH and CHPAH subgroups were younger than those in the CTPAH subgroup. Subjects were either NYHA FC II or III, with a similar proportion of each functional classification in the three aetiology subgroups. Mean RVSP was elevated but mean TAPSE was normal for the whole cohort.
However, there was no significant difference in either mean RVSP or mean TAPSE among the aetiology subgroups.
The 6MWD and the end-exercise gas exchange data for each of the three aetiology subgroups are presented in Table 2 and the mean change in _ VO 2 , _ VCO 2 , S p O 2 and HR during the 6MWT are shown in Figure 1 . While no significant difference was observed in 6MWD or HR between the subgroups, CTPAH and CHPAH subjects had a lower mean _ VO 2 and _ VCO 2 during and at end of the 6MWT when compared with IPAH subjects. However, there was no significant difference in _ VO 2 and _ VCO 2 among groups when corrected for body mass (mL/kg/min). CHPAH subjects also had significantly lower mean end-exercise _ V E and O 2 pulse compared with IPAH subjects, and desaturated to a greater extent during the 6MWT with a much lower end-exercise There was no significant difference in end-exercise _ V E / _ VCO 2 and P ET CO 2 among groups. Moreover, the change in _ V E / _ VCO 2 and P ET CO 2 from pre-to endexercise was not significantly different among groups.
Comparisons of 6MWD and gas exchange by NYHA functional classification are shown in Figure 2 . Fiftytwo subjects belonged to FC II and 24 to FC III. Aetiology of PAH was not significantly different between FC II and III (Table 1) . Compared with FC II, the FC III subjects had significantly lower 6MWD and endexercise _ VO 2 expressed in absolute (FC III: 0.76 AE 0.33 L/min; FC II: 0.99 AE 0.35 L/min, P = 0.008) and relative to body mass ( Fig. 2 , P < 0.01). There was no significant difference in the end-exercise _ V E and _ VCO 2 FC II and FC III subjects. FC II subjects did have a significantly higher mean end-exercise P ET CO 2 ( Fig. 2 , P < 0.01) and oxygen pulse (FC II: 7.4 AE 2.2 mL/beat; FC III: 5.9 AE 2.2 mL/beat, P < 0.01) and a lower mean end-exercise _ V E / _ VCO 2 ( Fig. 2 , P < 0.01) when compared with FC III subjects.
Comparison of changes in _ V E / _ VCO 2 and P ET CO 2 during the 6MWT for patients on monotherapy (n = 28) and triple therapy (n = 20) is shown in Figure 3 . There was no significant difference in 6MWD between monotherapy and triple therapy patients (502 AE 111 m vs 499 AE 96 m, P = 0.92). Both monotherapy and triple therapy groups had similar _ V E / _ VCO 2 and P ET CO 2 pre exercise; however, while no change was observed in _ V E / _ VCO 2 and P ET CO 2 in the monotherapy group from pre-to end-exercise, patients on triple therapy demonstrated a significant increase in mean _ V E / _ VCO 2 and a decrease in mean P ET CO 2 . Comparison of the therapy groups showed that there were proportionally fewer CHPAH and more IPAH subjects for the triple therapy (IPAH, 10; CTPAH, 7; CHPAH, 3) compared with the monotherapy group (IPAH, 5; CTPAH, 8; CHPAH, 15) group (χ 2 = 8.6, df = 2, P = 0.013). In addition, the triple therapy tended to have more severe disease (Fisher's exact test, P = 0.047) compared with the monotherapy group (triple: FC II, 13; FC III, 7; monotherapy: FC II, 25; FC III, 3). There were no other differences between groups in terms of subject characteristics or echocardiography measurements.
DISCUSSION
To our best knowledge, this study is the first to report concurrent 6MWT and gas exchange measurements on three major subgroups of Group I PAH patients attending a tertiary referral centre. Our findings demonstrated that although no differences in end-exercise _ V E / _ VCO 2 and P ET CO 2 were found between the three subgroups, CHPAH and CTPAH subjects had a significantly lower _ VO 2 and _ VCO 2 during exercise compared with IPAH subjects. Whilst the absolute _ VO 2 and _ VCO 2 were higher in the IPAH group, this difference was removed when corrected for body mass. This suggests that the IPAH group tended to be larger, with potentially greater muscle mass that resulted in a higher absolute O 2 utilization and CO 2 production at the exercising skeletal muscle. CHPAH subjects also had more significant desaturation during the 6MWT with a much lower end-exercise S p O 2 compared with IPAH and CTPAH Figure 1 Changes in oxygen uptake, carbon dioxide production, saturation and heart rate during the 6-min walk test. Data are mean AE SEM. *P < 0.05 versus the idiopathic and connective tissue groups. SEM, standard error of the mean; S p O 2 , oxygen saturation; _ VCO 2 , carbon dioxide production; _ VO 2 , oxygen uptake. , congenital; , connective tissue; , idiopathic.
subjects. When considered as a whole group, subjects who had a higher FC also had poorer gas exchange as characterized by higher _ V E / _ VCO 2 and lower P ET CO 2 . Moreover, a higher FC was associated with lower 6MWD. In addition, subjects on triple therapy had significantly higher end-exercise _ V E / _ VCO 2 and lower P ET CO 2 when compared with those on monotherapy despite having similar 6MWD.
Combining gas exchange measurements with the 6MWT requires specialist equipment and expertise and as such only a few studies to-date have reported exercise gas exchanges responses in PAH. Deboeck et al. 16 examined the physiological responses in 20 PAH patients during the 6MWT and found that the mean 6MWD and end-exercise _ VO 2 to be similar to those reported in our study (450 m and 0.90 L/min, respectively). PAH patients in their study were of mixed aetiologies including IPAH, CTPAH, CHPAH, portal hypertension-and fenfluramine-related PAH. However, no differentiation was made between these subsets of Gas exchange during 6MWT in PAH patients. More recently, Mainguy et al. 21 compared physiological responses to 6MWT, incremental exercise test, incremental shuttle walk test and endurance shuttle walk test in 21 PAH patients consisting of IPAH, CTPAH, CHPAH and heritable PAH. The authors reported a similar 6MWD as our current study (447 m) and a similar end-exercise _ VO 2 . However, no differentiation was made between the different aetiologies.
We found that the absolute _ VO 2 and _ VCO 2 for the IPAH group were higher than the other two groups (Table 2, Fig. 1 ). This difference was removed when _ VO 2 and _ VCO 2 were expressed relative to body mass ( Table 2 , Fig. 1 ). However, the higher absolute _ VO 2 required, as revealed by these gas exchange measurement, suggests that there would be slightly greater demands on for oxygen delivery (cardiac output) in the IPAH group during the 6MWT. Indeed, the fact that end-exercise O 2 pulse (surrogate for stroke volume) was higher and that HR tended to be higher would suggest that cardiac output was likely higher for the IPAH group compared with the others.
Our results did not find any significant difference in end-exercise _ V E / _ VCO 2 or P ET CO 2 between the three aetiology subgroups nor any change from pre-to endexercise. However, when categorized by their FC, FC III subjects tended to have shorter 6MWD and higher end-exercise _ V E / _ VCO 2 and lower P ET CO 2 . Whilst it is well documented that subjects with higher FC have shorter 6MWD, 22 our study is the first to report that PAH patients with higher FC have higher end-exercise _ V E / _ VCO 2 and lower P ET CO 2 during the 6MWT. We also found that changes in gas exchange response were sensitive to disease severity based on pharmacotherapy. This is a novel finding. Current management guidelines recommend a progressive uptitration in pharmacotherapy as the disease progresses. 23 As a result, individuals on triple therapy, whilst possibly well compensated, may well have more advanced disease compared with those on monotherapy. If we looked at the 6MWD alone, this would not be obvious. However, we found that triple therapy group tended to have more severe PAH patients when compared with the monotherapy group. Interestingly, we found that our triple therapy group contained more IPAH and fewer CHPAH patients when compared with the monotherapy group. When we compared the three groups alone (Table 2) , we found that _ V E / _ VCO 2 and P ET CO 2 responses during the 6MWT were independent of disease subtype. Hence, the fact that the triple therapy group had more IPAH patients and fewer CHPAH patients should make no difference to the gas exchange response to the 6MWT. We would argue that individuals with more severe disease have worse gas exchange response to exercise. In our triple therapy and monotherapy groups, a poorer gas exchange response to exercise (i.e. increase in _ V E / _ VCO 2 and a decrease in P ET CO 2 ) was independent of the 6MWD.
To date, the majority of studies examining the relationship between gas exchange and maximal CPET in PAH patients demonstrated a typical pattern of a reduced _ VO 2peak , peak work rate, anaerobic threshold (AT) and P ET CO 2 . In addition, an elevated _ V E / _ VCO 2 slope and functional dead space (V D /V T ) ventilation during maximal CPET were previously demonstrated in PAH patients. 24 In their landmark study, Yasunobu et al. 25 proposed an inverse hyperbolic relationship between P ET CO 2 and _ V E / _ VCO 2 measured at AT which categorized disease likelihood for PAH. Individuals with the highest _ V E / _ VCO 2 and lowest P ET CO 2 at AT were categorized as most likely to have PAH and with worse severity.
The hallmark of ventilatory dysfunction in PAH is hyperventilation characterized by an elevated _ V E / _ VCO 2 . Accompanying this is a decreased P ET CO 2 and arterial hypocapnia. Both of these factors have been linked to poor prognosis. Hoeper et al. 26 note that the extent to which IPAH patients hyperventilate is related to the extent of the disease, cardiac dysfunction and impaired oxygen delivery. In their retrospective study of 101 IPAH patients, these authors found that hypocapnia at rest and during exercise correlated with low cardiac output and was an independent predictor of survival. 26 Similarly, Wensel et al. have also demonstrated that in PAH, individuals with elevated _ V E / _ VCO 2 at rest and during exercise have poorer survival. 27, 28 The exact mechanism of the abnormal ventilatory response in PAH remains unclear; however, several possible interacting mechanisms have been proposed including increased feedback from skeletal muscle ergo/metaboreceptors, secondary to a reduced cardiac output during exercise, and increased firing from peripheral chemoreceptors, both leading to an increased ventilatory drive.
In summary, the results of this study suggested that the addition of gas exchange analysis to 6MWD correlated better with disease severity than 6MWD alone. Whilst gas exchange abnormalities could be measured during CPET, the use of a portable system during the 6MWT would negate the requirement for medical supervision. Moreover, patients do not have to exercise on a fixed ergometer in the 6MWT, such as a treadmill or a cycle ergometer, of which they are unfamiliar.
We were unable to obtain right heart catheter data for all subjects at the time when their first 6MWT was conducted. Hence, we relied on the RVSP as a surrogate marker of the pulmonary arterial pressures. Nonetheless, the echocardiograms were performed on our PAH patients by the same sonographer and reported by the same Cardiologist. Second, PAH is a disease of significant heterogeneity and we have only studied a limited cohort of Group I patients. It is possible that other groups of PAH patients may have different gas exchange responses to the 6MWT which is beyond the scope of this study. Another potential limitation to this study is the imbalance of patient subgroups in the therapy groups, with the triple therapy group having more IPAH and fewer CHPAH patients. Given that our comparison of the IPAH, CTPAH and CHPAH groups, independent of pharmacotherapy found no difference in the gas exchange among groups (see Table 2 ), we would argue that differences in the disease subgroups has no bearing on the overall result.
In conclusion, our study reported that gas exchange measurements including _ V E / _ VCO 2 and P ET CO 2 can be performed during the 6MWT. Results of this study could provide clinicians and researchers the opportunity to incorporate these relatively simple measures into clinical practice and add incremental value in the management of PAH patients.
